great post millim. it points out the process that Anteotech has...

great post millim. it points out the process that Anteotech has to go thru to get to the point of signing commercial deals for anteotech's CET

it's also interesting the change David has made with our lifescience division over the last year +.

eugeni was halted, a high % of the lifesience staff are gone or moved to different roles within the company. quite a significant change.

there has been kpi's missed, thats a fact, but why ???

maybe here's a clue. here are the pricing of 2 anteobind products.






thats very expensive. so what has David done? he's got the lab coats to develop a new product. Anteobind NXT. in the last couple of quarterlies management have shown cost reductions, ease of use and performance improvement, but yesterday gave the biggest clue

David discusses anteobind NXT at 13.40 and 23.15 minutes



highlights being

- available at a significantly reduced price point, cost point is now compatible to what they are using
- anteobind is validated and released to some poc companies
- formal launch in a couple of weeks
- still produces sensitivity enhancement, ease of use and reduction in antibody costs and labour

so David inherited a failed eugeni program and an over staffed division. he pivoted and changed course. from all the published papers using anteobind, it certainly works, found a couple new ones the last week. so why no deals? could it be anteobind cost so much more than the products companies were already using?

so what did David and the team do, create a new product. proved cost reductions for clients, improved sensitivity and ease of use. then get anteobind NXT validated by POC companies and most importantly realign pricing to competitors product by significantly reducing the price point.

formal launch in a couple of weeks and a couple of big companies getting close to deals.

time will tell if it's right but the road to commercialisation is never a straight line and just because commercialisation hasn't happened yet doesn't mean it won't.

2024 the year of ado (who said that?)